Introduction
============

In orthopaedic and trauma surgery, local application of antibiotics allows drug delivery in compartments poorly accessible to systemic administration, and the carrier material can help manage dead space [@B1]-[@B3]. Over the last decades, polymethylmethacrylate (PMMA) bone cement has become the standard of care carrier material [@B1], [@B2], [@B4], [@B5]. However, PMMA is not resorbable, implying the disadvantages of incomplete drug release and requirement of secondary removal [@B2], [@B5]-[@B7]. For many practical and historical reasons, the antibiotics added to PMMA are mostly limited to glycopeptides, such as vancomycin and teicoplanin, aminoglycosides, such as gentamicin or tobramycin, or clindamycin [@B1], [@B4], [@B5], [@B8].

Longer lasting release kinetics than from PMMA would be desirable, as a very high initial peak is usually followed by prolonged and mostly subtherapeutic release after some days [@B9]-[@B12]. Calcium sulphate (CaSO~4~) is a material widely used as a bone void filler and carrier for local delivery of antibiotics, with the particular advantage of resorbing within months [@B2], [@B13]. Promising clinical experience with this carrier material has already been reported, both with aminoglycosides and vancomycin [@B2], [@B7], [@B12], [@B14], [@B15]. Furthermore, its compatibility with many more antibiotics has already been described as well [@B16]-[@B23]. However, most studies only examined short-term release. Studies testing release over 6 weeks, a duration of treatment usual for bone and joint infections, are not so common [@B22]-[@B25]. Regarding the complexity of the spectrum of bacteria encountered in bone and joint infections, a larger choice of antibiotics would be favourable [@B26]-[@B28].

This study aims at describing compatibility with the carrier material and release kinetics in the setting of an *in vitro* elution experiment of new combinations of antibiotics added to CaSO~4~. In contrast to most other studies, this experiment provides observations over a prolonged, clinically relevant period of 6 weeks. The effect of using a biological elution fluid, instead of simple electrolytic solutions, is tested as well, since the concomitant presence of proteins may significantly reduce the antibacterial effect of antibiotics [@B29].

Methods
=======

Preparation of the pellets
--------------------------

CaSO~4~ hemihydrate was specifically produced for this experiment (lot E09-0019, RMS Foundation, Bettlach, Switzerland). For the sake of clarity, the powdered, dehydrated form will be denominated CaSO~4~ hemihydrate, while CaSO~4~ will be used for the dihydrate. CaSO~4~ in analytical quality (Ref. 12056, lot 70660, Honeywell Riedel-de-Haen, Seelze, Germany) was autoclaved four times at 134 °C for 60 min, with drying performed at 105 °C. The powder was then grinded in a disk mill (Pulverisette 13, Fritsch, Idar-Oberstein, Germany), followed by milling for 5 min at 400 RPM in a planetary mill (Pulverisette 5, Fritsch, Idar-Oberstein, Germany) adding 100% w/w zirconia beads and 20% w/w ethanol. To confirm the hemihydrate nature, a sample of the powder was heated up at 400 °C (N20/14 furnace, Nabertherm, Germany). The resulting weight loss was 6.1%, which is close to the theoretical value of 6.2% expected for the dehydration of CaSO~4~ hemihydrate into the anhydrous form. According to x-ray diffraction analysis (PW1800 x-ray diffractometer, PANalytical, Almelo, Netherlands), the powder contained 88% hemihydrate, 5% dihydrate and 7% anhydrate. Electron-beam microscopy (S360, Leica Microsystems, Wetzlar, Germany), confirmed the typical rod-like appearance of alpha-hemihydrate.

Pellets were manufactured using silicone moulds, as described elsewhere [@B12], [@B30]. The CaSO~4~ hemihydrate was mixed manually with the antibiotic powder, until macroscopically evenly blended. The antibiotics used are listed in Table [1](#T1){ref-type="table"}. Note that drugs for medical use might contain excipients and preservatives [@B31]. The proportion of antibiotic to CaSO~4~ hemihydrate was 8%:92% w/w. Weighting was done on a microgram balance (XS203S, Mettler-Toledo, Greifensee, Switzerland). Mean error for antibiotic and CaSO~4~ hemihydrate weighting was 0.5% (SD 0.004) and 0.03% (SD 0.0005), respectively. At least 35% twice demineralized water was added to obtain a mouldable dough. Preparations with ceftriaxone required adding approximately twice as much water. Excess water was removed by drying the pellets in a dessicator for 36 hours. Despite a prolonged dessication process, imipenem-cilastatin hindered hardening of the CaSO~4~, and had to be discarded from further tests.

Elution experiment
------------------

For every antibiotic, 5 g of pellets were placed in each of four closed glass tubes. The elution experiment was run in triplicate, while the fourth tube allowed sampling of whole pellets for agar diffusion tests. Each tube was filled with 10 ml of elution fluid, exchanged daily by pouring it out and refilling. As the aim of the experiment was to assess stability and activity of the antibiotics over a prolonged period of time, no thorough rinsing of the pellets was performed in order to avoid accidental losses of material and drug washout. The experiment was run once with isotonic phosphate-buffered saline (PBS, art. G227, lot 0922327, Grogg Chemie, Stettlen-Deisswil, Switzerland), and then repeated with bovine plasma (IBV-K2 EDTA, lot 11035, Innovative Research, Novi, MI, USA) for those antibiotics that showed prolonged stability in the first phase. Except for the required daily manipulations, the tubes where kept at 37 °C for a total of 42 days. The same person (S.F.) performed all manipulations every day for the whole experiment, thus ensuring technical continuity. Enoxaparin-sodium (Clexane, Sanofi-Aventis, Meyrin, Switzerland) was added at 0.01 mg/ml to the plasma to avoid coagulation in the presence of CaSO~4~. Preliminary tests had been performed to verify dosing and to exclude interference with antibiotic assays.

Antibiotic assays
-----------------

Concentrations of the antibiotics were measured by high performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) from samples collected daily for the first 8 days, on day 10 and 14, and then weekly until day 42. One ml of elution fluid was sampled from every test tube in polypropylene cryotubes (Nunc, Thermo Scientific, Reinach, Switzerland), immediately shock-frozen in ethanol/dry ice, and then stored at -80 °C. After thawing, assaying was performed as a batch at the end of each phase of the experiment. All measures were done trice. Technical details have been published previously [@B8]. The lower limits of quantification (LOQ) of every antibiotic is listed in Table [1](#T1){ref-type="table"}.

Antibacterial activity of the antibiotics was verified by Kirby-Bauer disc diffusion tests on days 1, 2, 3, 5, 7, 10, 14 and then weekly until day 42. Dry paper discs 6 mm in diameter (Becton Dickinson, Heidelberg, Germany) were impregnated with 25 µl of elution fluid and placed on Mueller Hinton agar (Biomérieux, Geneva, Switzerland) plates inoculated with an appropriate reference bacterium (Table [1](#T1){ref-type="table"}), following the EUCAST protocol [@B8], [@B32], [@B33]. These assays were performed continuously during the experiment. A whole pellet was also sampled from the fourth tube, and placed directly on the agar. Inhibition zones were measured at the nearest mm after incubation for one day at 37 °C.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS Version 21 (SPSS Inc., Chicago, IL, USA). All results are presented as means of triplicate values and standard deviation (SD). A paired t-test was employed to assess the differences in antibiotic concentration between PBS and plasma. The level of significance was set at *p* \< 0.05. Graphical illustrations were made with Illustrator CS6 Version 16 (Adobe Systems, San Jose, California, USA). Simulations of release kinetics were performed with Excel 2010 (Microsoft, Redmond, Washington, USA), considering solubility of the antibiotics [@B34] and time to equilibrium.

Results
=======

Results from determination of concentration by LC-MS/MS of piperacillin, tazobactam, ceftazidime, cefepime and meropenem are illustrated in Figure [1](#F1){ref-type="fig"}. Corresponding results from disc diffusion tests of these antibiotics are presented in Figure [2](#F2){ref-type="fig"}. As these antibiotics showed a relatively rapid elimination, they were not considered for further testing in plasma.

Results for flucloxacillin, cefuroxime, ceftriaxone, ciprofloxacin, levofloxacin and clindamycin, including statistical analysis, are presented in Figure [3](#F3){ref-type="fig"} for quantification by LC-MS/MS and Figure [4](#F4){ref-type="fig"} for inhibition zone size from disc diffusion tests. P-values \< 0.05 could be identified for flucloxacillin, cefuroxime, ciprofloxacin and clindamycin. A major and potentially relevant difference could however only be observed for ciprofloxacin. Except for ciprofloxacin, results from the plasma test series tended towards higher concentrations than in PBS. Regarding the disc diffusion tests as shown in Figure [4](#F4){ref-type="fig"}, direct comparison from one antibiotic to another shall not be made as different reference organisms have been used, depending on the antibiotic spectrum of each drug.

Results from disc diffusion assays with an entire pellet are not presented, as they provided congruent results with diffusion from paper discs, with technical issues limiting interpretability.

Sample results from the release simulations are illustrated in Figure [5](#F5){ref-type="fig"}, along with correlations of observed results from the elution experiment.

Discussion
==========

This study provides some new insights useful in optimizing local application of antibiotics to treat bone, joint, and implant-associated infections. In contrast to all the other tested antibiotic agents, ceftriaxone showed an elution profile corresponding to a slow release when used with CaSO~4~ as carrier material.

For application as a bone void filler or antibiotic carrier, CaSO~4~ hemihydrate in its alpha variant is generally preferred over the beta variant, as it provides a dehydrate less porous with a more predictable resorption behaviour [@B13], [@B35], [@B36]. While a product not commercially available was used for this experiment, internal verification confirmed that it was an alpha-hemihydrate of CaSO~4~. Determination of the exact proportion of the tested antibiotics in the final pellets would require a complex chemical analysis, as water has to be added in excess during preparation of CaSO~4~, which evaporates during the curing process. However, the technique described in this study produces pellets containing approximately as much antibiotic as commonly used in clinical application [@B2], [@B7], [@B12], [@B14], [@B15], [@B30]. The very high porosity of CaSO~4~ (\>2 m^2^/g) [@B36] might have been increased due to the addition of antibiotics, as it has been demonstrated for other materials [@B6], [@B37]. Increasing the concentration of antibiotics increases release from CaSO~4~, probably due to increased porosity [@B19], [@B22]. This is well known for PMMA, and increasing porosity in such a way, and others, is used to increase antibiotic release in clinical application [@B6], [@B38]-[@B40]. Even if the ratio of external surface to volume influences drug elution from CaSO~4~, porosity remains the main material-based predictor of antibiotic elution in calcium-based carriers [@B22], [@B23], [@B41]. With the exception of a potential calcium salt formation, there is no covalent binding of the added drug. Thus, a large proportion of the antibiotic is usually free to diffuse. Technical variability, such as inhomogeneity of the pellets and residual fluid during daily exchange, most likely explains differences in concentrations observed between PBS and plasma for flucloxacillin, cefuroxime and clindamycin (Figures [3](#F3){ref-type="fig"} & [4](#F4){ref-type="fig"}), even if statistically significant differences could be identified for these antibiotics. Technical issues probably had an influence on results more important than many molecular aspects.

Elution experiments test many factors simultaneously. First, the compatibility of the drug with the chosen carrier material, particularly degradation of the drug due to any heat production during the manufacturing process [@B8], [@B42]. Second, the stability of the drug as it is exposed to the chosen physicochemical conditions over time. Most antibiotics suffer significant degradation being exposed to body temperature in aqueous solution [@B8], [@B21], [@B43], [@B44]. Third, exchange of the elution fluid greatly influences elimination of the drug, particularly for highly soluble molecules [@B42], [@B45]. In the setting of the current study, approximately 90% of the fluid has been exchanged on a daily basis, the rest remaining trapped among the pellets. All drugs tested, except ceftriaxone, showed an initial high peak, with a more or less rapid decrease of concentration and activity over time (Figures [1](#F1){ref-type="fig"} & [3](#F3){ref-type="fig"}). Considering subtotal daily fluid exchange, rapid decrease of concentration and activity can be explained by either rapid release or rapid degradation of the drug at body temperature in aqueous solution [@B8], [@B43], [@B44]. Rapid release depends on high solubility [@B42], and the fact that the carrier material does not bind the drug, which would delay its release [@B12]. The influence of solubility on antibiotic concentrations in an elution experiment is illustrated in Figure [5](#F5){ref-type="fig"}, where simulated release curves are compared to observed results. While most profiles correspond to agents with intermediate solubility, ceftriaxone shows an elution profile corresponding to a slow release limited by its solubility. Although antibiotic concentrations well above common minimal inhibitory concentrations have been observed for several weeks for flucloxacillin, cefuroxime, ciprofloxacin, levofloxacin and clindamycin in our experiment, their clinical significance remains unclear. The kinetics of wound fluid are unknown and may by different to this experimental setting. It can also be expected that any carrier material will be incorporated *in vivo* in a blood clot, which might alter elution kinetics, even if an equilibrium within the local compartment might be expected due to the slow release [@B46]. Generalisation beyond the general pharmacokinetic behaviour of the observed results into clinical practice remains limited.

In contrast to the other tested antibiotic agents, ceftriaxone shows a near-constant release. Despite additional water added during preparation, which is expected to have increased porosity [@B41]. This slow release can only be explained by formation of a depot within the CaSO~4~. When exposed in aqueous solution without CaSO~4~, this drug shows an intermediate stability, with near-complete degradation during the observation period of this study [@B8], [@B44]. Ceftriaxone, usually provided as a disodium salt, is known to bind and precipitate with Ca^++^ ions. This mechanism is implicated in the formation of biliary sludge or urolithiasis during treatment with ceftriaxone and caused complications due to *in vivo* precipitation of the drug after concomitant administration of both substances [@B47]-[@B49]. The kinetic solubility constant of ceftriaxone and calcium at 37 °C has been described as being between 0.162\*10^-5^ mol/l^2^ in crystalloid solution [@B49] and 4.2\*10^-5^ mol/l^2^ in plasma [@B47], with differences accounted for by considerations of the matrix and the proportion of protein-binding in biological fluids. This corresponds to a maximum solubility of ceftriaxone between 705 and 3\'594 mg/l, considering a molecular weight of 554.571 g/mol for ceftriaxone. However, precipitation of ceftriaxone in the presence of calcium is a complex phenomenon, as this couple has a wide metastable range, exceeding the solubility product by a factor of 10, favourably influenced by biological fluids [@B47]-[@B49]. Saturation of the solution is certainly exceeded when CaSO~4~ pellets are manufactured. The concentrations observed in the current experiment do not show a decrease as it would be if induced by hydrolysis at body temperature in aqueous solution [@B8], [@B44]. In addition, the observed concentrations remain around 100 mg/l after 24h of elution, which is far below the concentrations required to observe precipitation in biological fluids [@B47]-[@B49]. Thus, slow release from a depot of Ca-ceftriaxone can be postulated, with solubility limited by Ca^++^-saturation of the solution. To the best of our knowledge, this near-constant release over a long period has not been described so far, neither for ceftriaxone, nor for any other antibiotic carrier material used for local antibiotic application in orthopaedic surgery. The observed slow release of ceftriaxone from CaSO~4~ pellets would provide optimal kinetics, with sufficient drug concentration for a prolonged time of exposure. This is the essential pharmacodynamic parameter determining bacterial killing and treatment success by beta-lactam antibiotics in general, and ceftriaxone in particular [@B29], [@B50].

Particular strengths of this study are the length of the observation period, the use of a biological fluid, and that two different analytical methods have been used. It remains unknown how long exactly local antibiotics are required. In the current experiment, a period of 6 weeks had been chosen as it corresponds to commonly recommended duration of treatment protocols for bone and implant-associated infections [@B24], [@B25]. *in vitro* evidence supports that similar durations are required to eradicate biofilm by the action of antibiotics alone [@B11]. The experiments have been repeated in plasma in order to illustrate potential differences on antibiotic disposition between crystalloid and complex biological fluids. Protein binding of antibiotics has a known relevant effect on bacterial killing [@B29], [@B51]. However, only ciprofloxacin showed a marked decrease of concentration in plasma (Figure [3](#F3){ref-type="fig"}B). This was apparent only in LC-MS/MS assays. The decreased concentration might be due either to protein binding or to binding with calcium ions [@B51]. Nevertheless, no decrease of the antibacterial activity could be observed, but this might also be explained by a lack of sensitivity of disc diffusion tests (Figure [4](#F4){ref-type="fig"}). For the other antibiotics, the observed differences were smaller than the variability of the methods, even if statistical tests showed significant results. This is illustrated by the fact that the curves cross each other and that differences mostly are smaller than a 95% confidence interval of approximately 2 standard deviations would be. Differences between results from PBS and plasma also appear less than what might be expected as clinically relevant, whereas both test series show similar behaviours.

While antibiotic concentration has been determined by LC-MS/MS, antibacterial activity has been verified by disc diffusion test. Even if LC-MS/MS is a very specific method that should detect alterations of the molecule [@B52], biological activity of the tested drugs has been investigated as well. Both methods provided congruent results. However, results from the disc diffusion assays could not be used for quantification. The establishment of a calibration curve and serial dilution would have been required to ensure that measurements are performed in the window of linear dose-response [@B8], [@B53]. However, this additional analysis would have exceeded the setting and feasibility of this study. Interpretation of results from disk diffusion tests using entire pellets remains limited by many technical issues. Firstly, the quantity of antibiotics contained in the pellets was not standardized and decreased over time with dissolution of the carrier and elution of the drug. Secondly, contact of the pellets with the surface of the agar showed major variability. And lastly, a relevant number of pellets did not adhere sufficiently to the agar without breaking it and interrupting diffusion of the drug. For these reasons, results have not been shown in detail.

Plasma had been chosen instead of serum, as coagulation factors make up a large proportion of the protein content of blood. However, dissolution of CaSO~4~ saturates the solution with Ca^++^ ions, which are essential catalysts in various steps of the coagulation cascade [@B54]. Low molecular weight heparins were added to the plasma to avoid coagulation. While heparins with lithium ions are known to cause a matrix effect that might influence results from LC-MS/MS [@B55], the heparin used was enoxaparin-Na. Nevertheless, the absence of influence on results was verified for ceftriaxone, even if results from this test series are not shown. LC-MS/MS has a higher specificity than fluorescence polarisation assays, which are still standard in clinical routine for therapeutic drug monitoring [@B52], [@B56]. The results from disc diffusion assays are not influenced, considering comparable results between PBS and plasma series. But this might be solely due to the low sensitivity of this method.

Most quantification results showed a shouldering at 5-7 days. Technical issues probably explain this phenomenon. Even if all manipulations regarding the elution part of the experiment have been performed by the same person, variability of residual fluid in the test tubes at daily fluid exchange is the most probable explanation. Progressive alteration of the consistency of the pellets may have caused some difficulties during vortexing and fluid exchange, which could not be quantified in this study. As the pellets were manufactured manually, the material certainly suffered from some degree of inhomogeneity. This fact would certainly provide a very probable explanation for this shouldering as it was simultaneously observed for all tested antibiotic agents. Storage should not be an issue as the samples were shock-frozen and kept at -80 °C until assaying, a temperature that ensures stability of even the most fragile beta-lactams [@B43].

Last but not least, when discussing the choice of antibiotics for local application, cellular toxicity thresholds must be considered. This is particularly problematic for the quinolones [@B57]-[@B59]. Vancomycin, clindamycin, the aminoglycosides, and to a slightly lesser extend all beta-lactam antibiotics, all show low toxicity, offering broad margins for local application [@B58]-[@B60]. Although there is no such specific data available in the literature for ceftriaxone, the concentrations observed remained far below the toxicity threshold known for other cephalosporins [@B59]. Cell toxicity however is a time-dependant phenomenon [@B57], [@B58], [@B60]. Only suppositions can be made regarding toxicity of a prolonged exposure over weeks, as this never has been published to the best of our knowledge.

In conclusion, this study not only provide[s]{.ul} new insights allowing optimization of local antibiotic application with CaSO~4~ as a carrier material, but it also illustrates limits of classic elution experiments. Ceftriaxone appears to have a particular behaviour, not described so far, with a near-constant release at \~100 mg/l for the 6 weeks duration of the experiment. This observation may open new possibilities for the treatment of bone and joint infections.
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![Results from determination of concentration of piperacillin/tazobactam, ceftazidime, cefepime and meropenem by HPLC-MS, presented as means from triplicates, with error bars indicating standard deviations.](jbjiv03p0212g001){#F1}

![Results from determination of antibacterial activity of piperacillin-tazobactam, ceftazidime, cefepime and meropenem by disc diffusion test from the test series in PBS. Piperacillin and tazobactam had to be tested in combination for this assay. Data are presented as means of triplicates of the diameter of the zone of inhibition in mm, with error bars indicating standard deviation. The horizontal line at 6 mm indicates the diameter of the paper disc.](jbjiv03p0212g002){#F2}

![Results from determination of concentration in the elution fluids by HPLC-MS indicated for both PBS and plasma. In Fig. [3](#F3){ref-type="fig"}A, results for flucloxacillin, cefuroxime, and ceftriaxone are presented. Fig. [3](#F3){ref-type="fig"}B shows the results for ciprofloxacin, levofloxacin and clindamycin. Results are presented as means from triplicates with error bars indicating standard deviation, with statistical analysis of the comparison between results in PBS and plasma indicated in the legend.](jbjiv03p0212g003){#F3}

![Results from determination of antibacterial activity by disc diffusion test, indicating the diameter of the zone of inhibition in mm. Data presented as means from triplicates, with error bars indicating standard deviation. In Fig. [4](#F4){ref-type="fig"}A, results of flucloxacillin, cefuroxime and ceftriaxone are shown. Fig. [4](#F4){ref-type="fig"}B provides the results for ciprofloxacin, levofloxacin and clindamycin. The horizontal line at 6 mm indicates the diameter of the paper disc. Direct comparison from one antibiotic to another shall not be made as different reference organisms have been used.](jbjiv03p0212g004){#F4}

![Calculation of the expected antibiotic concentrations after each incubation step using three assumptions: (o) the solubility of the drug is limited to 105 mg/L (e.g. Ceftriaxone); (Δ) the drug is fully soluble and the system is fully equilibrated at the end of each incubation; (□) the drug is fully soluble, but only 85% of the drug have time to diffuse out of the pellets at the end of each incubation. To assess the validity of these calculations, some of the experimental results are plotted: (o) Ceftriaxone; (x) Cefepime; (▲) ceftazidime; (+) meropenem.](jbjiv03p0212g005){#F5}

###### 

List of antibiotics used in the experiments. The lower limit of quantification (LOQ) of the LC-MS/MS assay used is listed. The reference bacterium used for disc diffusion assays is also included.

  Antibiotic                Product Table        Supplier                                       LC-MS/MS LOQ                                 Disk Diffusion
  ------------------------- -------------------- ---------------------------------------------- -------------------------------------------- ----------------------
  Flucloxacillin            Floxapen^®^          Actavis, Regensdorf, Switzerland               0.1 mg/L                                     S. aureus ATCC 25923
  Piperacillin+tazobactam   Tazobac^®^           Actavis, Regensdorf, Switzerland               Piperacillin 0.08 mg/LTazobactam 0.05 mg/L   E.coli ATCC 35218
  Cefuroxime                Zinacef^®^           GlaxoSmithKline, Münchenbuchsee, Switzerland   0.1 mg/L                                     E. coli ATCC 25922
  Ceftriaxone               Rocephin^®^          Roche Pharma, Reinach, Switzerland             0.5 mg/L                                     E. coli ATCC 25922
  Ceftazidime               Fortam^®^            GlaxoSmithKline, Münchenbuchsee, Switzerland   0.1 mg/L                                     E. coli ATCC 25922
  Cefepime                  Cefepime OrPha^®^    OrPha Pharma, Küsnacht, Switzerland            0.05 mg/L                                    E. coli ATCC 25922
  Imipenem+cilastatin       Tienam^®^            MerckSharp&Dohme, Lucerne, Switzerland         Imipenem 0.05 mg/L                           E. coli ATCC 25922
  Meropenem                 Analytical quality   AstraZeneca, Grafenau, Switzerland             0.05 mg/L                                    E. coli ATCC 25922
  Ciprofloxacin             Analytical quality   Bayer, Zürich, Switzerland                     0.1 mg/L                                     E. coli ATCC 25922
  Levofloxacin              Analytical quality   Sanofi-Aventis, Vernier, Switzerland           0.1 mg/L                                     E. coli ATCC 25922
  Clindamycin               Analytical quality   Pfizer, Zürich, Switzerland                    0.1 mg/L                                     S. aureus ATCC 25923
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